



US00937189B2

(12) United States Patent
Dhuppad et al.**(10) Patent No.: US 9,937,189 B2**
(45) Date of Patent: *Apr. 10, 2018**(54) STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE****(71) Applicant: GLENMARK SPECIALTY S.A., La**
Chaux-de-Fonds (CH)**(72) Inventors: Ulhas R. Dhuppad, Maharashtra (IN);**
Ashok Katkurwar, Maharashtra (IN);
Yashwant Gupta, Maharashtra (IN);
Rajesh Ankam, Maharashtra (IN);
Chandrakant Dhatrak, Maharashtra
(IN)**(73) Assignee: GLENMARK SPECIALTY S.A., La**
Chaux-de-Fonds (CH)**(*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 15/210,692**(22) Filed: Jul. 14, 2016****(65) Prior Publication Data**

US 2017/0189422 A1 Jul. 6, 2017

Related U.S. Application Data**(63)** Continuation-in-part of application No. 15/183,534, filed on Jun. 15, 2016, which is a continuation of application No. 14/662,128, filed on Mar. 18, 2015, now Pat. No. 9,370,483, which is a continuation-in-part of application No. 14/483,837, filed on Sep. 11, 2014, now Pat. No. 9,078,923, which is a continuation-in-part of application No. PCT/IB2014/064251, filed on Sep. 4, 2014.**(30) Foreign Application Priority Data**

Sep. 13, 2013 (IN) 2975/MUM/2013

(51) Int. Cl.**A61K 31/58** (2006.01)
A61K 9/00 (2006.01)
A61K 9/10 (2006.01)
A61K 31/335 (2006.01)
A61K 47/36 (2006.01)
A61K 47/38 (2006.01)**(52) U.S. Cl.**CPC **A61K 31/58** (2013.01); **A61K 9/0043**
(2013.01); **A61K 9/10** (2013.01); **A61K 31/335**
(2013.01); **A61K 47/36** (2013.01); **A61K 47/38**
(2013.01)**(58) Field of Classification Search**CPC .. **A61K 2300/00**; **A61K 31/335**; **A61K 31/58**;
A61K 47/36; **A61K 47/38**; **A61K 9/0043**;
A61K 9/10; **A61K 31/00**; **A61K 47/02**;
A61K 47/186; **A61K 47/26**

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

4,871,865 A 10/1989 Lever, Jr. et al.
4,923,892 A 5/1990 Lever, Jr. et al.
5,837,699 A 11/1998 Sequeira et al.
6,127,353 A 10/2000 Yuen et al.
6,841,146 B2 1/2005 Haslwanter et al.
7,977,376 B2 7/2011 Singh et al.
8,399,508 B2 3/2013 Singh et al.
9,078,823 B2 7/2015 Dhuppad et al.
9,078,923 B2 * 7/2015 Dhuppad A61K 9/0043
9,370,483 B2 * 6/2016 Dhuppad A61K 31/335
2004/0097474 A1 5/2004 Cagle et al.
2006/0110328 A1 5/2006 Cagle et al.
2008/0058296 A1 3/2008 Chaudry
2012/0121653 A1 5/2012 Jenkins et al.
2015/0099725 A1 4/2015 Khairatkar-Joshi et al.
2015/0272966 A1 10/2015 Khairatkar-Joshi et al.

FOREIGN PATENT DOCUMENTS

WO WO-1995020393 A1 8/1995
WO WO-2001026658 4/2001
WO WO-2006057769 A2 6/2006
WO WO-2009003199 A1 12/2008
WO WO-2010025236 A1 3/2010
WO WO-2011008923 A2 1/2011
WO WO-2011141929 A2 11/2011
WO WO-2012094283 A2 7/2012
WO WO-2014092346 A1 6/2014

OTHER PUBLICATIONS

Avicel® RC-591, Product Specification Bulletin, Feb. 2009.
Austin, et al., Mometasone Furoate is a Less Specific Glucocorticoid than Fluticasone Propionate, Eur Respir J, 2002, 20:1386-1392.
Baja, et al., Benefits of Skin Prick Tests for Allergic Rhinitis, The Internet Journal of Otorhinolaryngology, 2006, 6:1.
International Search Report for International Application PCT/IB2014/064251 dated Nov. 19, 2014, pp. 1-13.
Johnson, M., Ph.D., Development of Fluticasone Propionate and Comparison with Other Inhaled Corticosteroids, J Allergy Clin Immunol, Apr. 1998, 101:4:P2:S434-S439.

(Continued)

Primary Examiner — Audrea Buckley

(74) Attorney, Agent, or Firm — Blank Rome LLP**(57) ABSTRACT**

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

36 Claims, No Drawings